La línea de productos de hematología de BeOne Medicines marca el rumbo de la próxima era de innovación en el cáncer de células B en la EHA 2026

Key Takeaway: BeOne Medicines is positioning its hematology product line as a key player in the future of B-cell cancer innovation, as highlighted at EHA 2026. The company's focus on advancing treatments reflects ongoing developments in the field. Further details on specific innovations or product features were not provided in the article.